FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999563756> ?p ?o ?g. }

• W1999563756 endingPage "387" @default.
• W1999563756 startingPage "375" @default.
• W1999563756 abstract "Migraine is a costly, recurrent condition that affects 28 million individuals in the United States yet remains underdiagnosed and undertreated. In 2004, the U.S. Food and Drug Administration approved topiramate for the prevention of migraine in adults, joining three other agents with this indication: divalproex sodium, propranolol, and timolol. We evaluated the role of topiramate in the treatment of migraine based on published literature and our clinical experiences. A qualitative systematic search of the literature from January 1966–December 2004 was conducted by using MEDLINE, and other pertinent literature was reviewed. Three large, randomized, placebo-controlled trials of topiramate for migraine prevention in individuals experiencing 3–12 attacks/month have been published, as have several small studies and a comparator trial with propranolol. Based on the results of these studies, 100 mg/day is the optimum topiramate dosage in terms of efficacy and tolerability. Using that dosage, the number of migraine attacks/month decreased by approximately two. Several other secondary outcome measures were also significantly reduced including the number of days/month with migraine and the use of acute treatment/attack. Suboptimal efficacy was shown with 50 mg/day, whereas 200 mg/day caused considerably more tolerability issues. Paresthesia was dose related and the most common cause of attrition. Cognitive dysfunction and weight loss were also commonly reported. The reduction by two migraines/month demonstrated with topiramate in clinical trials is similar to the published results for other preventive agents, though most of those studies were small, antiquated, and poorly designed. In contrast, the topiramate trials enrolled a larger number of patients and closely adhered to the International Headache Society research recommendations, strengthening the quality of results. Topiramate 100 mg/day is an effective option in adults who require migraine prophylaxis. Although the published efficacy results of the various migraine preventive agents are comparable, the superior study design of the topiramate trials warrants consideration of topiramate as an agent of choice for migraine prevention. Future studies of any preventive agent should include more refined quality-of-life outcomes." @default.
• W1999563756 created "2016-06-24" @default.
• W1999563756 creator A5006390427 @default.
• W1999563756 creator A5046919934 @default.
• W1999563756 creator A5064921789 @default.
• W1999563756 date "2006-03-01" @default.
• W1999563756 modified "2023-10-15" @default.
• W1999563756 title "Topiramate for Migraine Prevention" @default.
• W1999563756 cites W1842552614 @default.
• W1999563756 cites W1963569078 @default.
• W1999563756 cites W1970386351 @default.
• W1999563756 cites W1973511428 @default.
• W1999563756 cites W1987960446 @default.
• W1999563756 cites W2016030981 @default.
• W1999563756 cites W2026080368 @default.
• W1999563756 cites W2045567183 @default.
• W1999563756 cites W204766049 @default.
• W1999563756 cites W2048239616 @default.
• W1999563756 cites W2052258972 @default.
• W1999563756 cites W2062526596 @default.
• W1999563756 cites W2064006234 @default.
• W1999563756 cites W2079722143 @default.
• W1999563756 cites W2083727172 @default.
• W1999563756 cites W2104531364 @default.
• W1999563756 cites W2104820313 @default.
• W1999563756 cites W2108682124 @default.
• W1999563756 cites W2119011129 @default.
• W1999563756 cites W2123978981 @default.
• W1999563756 cites W2128359221 @default.
• W1999563756 cites W2147394426 @default.
• W1999563756 cites W2149133494 @default.
• W1999563756 cites W2152382571 @default.
• W1999563756 cites W2158846562 @default.
• W1999563756 cites W2164727670 @default.
• W1999563756 cites W2166530830 @default.
• W1999563756 cites W2410612002 @default.
• W1999563756 cites W3015167373 @default.
• W1999563756 doi "https://doi.org/10.1592/phco.26.3.375" @default.
• W1999563756 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16503717" @default.
• W1999563756 hasPublicationYear "2006" @default.
• W1999563756 type Work @default.
• W1999563756 sameAs 1999563756 @default.
• W1999563756 citedByCount "33" @default.
• W1999563756 countsByYear W19995637562012 @default.
• W1999563756 countsByYear W19995637562013 @default.
• W1999563756 countsByYear W19995637562014 @default.
• W1999563756 countsByYear W19995637562016 @default.
• W1999563756 countsByYear W19995637562018 @default.
• W1999563756 countsByYear W19995637562022 @default.
• W1999563756 countsByYear W19995637562023 @default.
• W1999563756 crossrefType "journal-article" @default.
• W1999563756 hasAuthorship W1999563756A5006390427 @default.
• W1999563756 hasAuthorship W1999563756A5046919934 @default.
• W1999563756 hasAuthorship W1999563756A5064921789 @default.
• W1999563756 hasConcept C118552586 @default.
• W1999563756 hasConcept C126322002 @default.
• W1999563756 hasConcept C142724271 @default.
• W1999563756 hasConcept C168563851 @default.
• W1999563756 hasConcept C187212893 @default.
• W1999563756 hasConcept C197934379 @default.
• W1999563756 hasConcept C204787440 @default.
• W1999563756 hasConcept C27081682 @default.
• W1999563756 hasConcept C2777683783 @default.
• W1999563756 hasConcept C2778073030 @default.
• W1999563756 hasConcept C2778186239 @default.
• W1999563756 hasConcept C2778375690 @default.
• W1999563756 hasConcept C2778541695 @default.
• W1999563756 hasConcept C2780564907 @default.
• W1999563756 hasConcept C2781092963 @default.
• W1999563756 hasConcept C42219234 @default.
• W1999563756 hasConcept C535046627 @default.
• W1999563756 hasConcept C71924100 @default.
• W1999563756 hasConceptScore W1999563756C118552586 @default.
• W1999563756 hasConceptScore W1999563756C126322002 @default.
• W1999563756 hasConceptScore W1999563756C142724271 @default.
• W1999563756 hasConceptScore W1999563756C168563851 @default.
• W1999563756 hasConceptScore W1999563756C187212893 @default.
• W1999563756 hasConceptScore W1999563756C197934379 @default.
• W1999563756 hasConceptScore W1999563756C204787440 @default.
• W1999563756 hasConceptScore W1999563756C27081682 @default.
• W1999563756 hasConceptScore W1999563756C2777683783 @default.
• W1999563756 hasConceptScore W1999563756C2778073030 @default.
• W1999563756 hasConceptScore W1999563756C2778186239 @default.
• W1999563756 hasConceptScore W1999563756C2778375690 @default.
• W1999563756 hasConceptScore W1999563756C2778541695 @default.
• W1999563756 hasConceptScore W1999563756C2780564907 @default.
• W1999563756 hasConceptScore W1999563756C2781092963 @default.
• W1999563756 hasConceptScore W1999563756C42219234 @default.
• W1999563756 hasConceptScore W1999563756C535046627 @default.
• W1999563756 hasConceptScore W1999563756C71924100 @default.
• W1999563756 hasIssue "3" @default.
• W1999563756 hasLocation W19995637561 @default.
• W1999563756 hasLocation W19995637562 @default.
• W1999563756 hasOpenAccess W1999563756 @default.
• W1999563756 hasPrimaryLocation W19995637561 @default.
• W1999563756 hasRelatedWork W1964990613 @default.
• W1999563756 hasRelatedWork W1973308362 @default.
• W1999563756 hasRelatedWork W2107594135 @default.

• next